Atlas Trials

Helsinn Healthcare SA

32 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Helsinn Healthcare SA

RecordFirmDate
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC) (NCT06904235)Helsinn Healthcare SA2025-07-07
A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers (NCT06840769)Helsinn Healthcare SA2023-06-17
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations (NCT05222165)Helsinn Healthcare SA2021-10-01
Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) (NCT04817189)Helsinn Healthcare SA2021-02-01
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT03743051)Helsinn Healthcare SA2019-03-05
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer (NCT03403712)Helsinn Healthcare SA2018-03-16

Track Helsinn Healthcare SA automatically

Every clearance here is in the API, with alerts when new ones post.